Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Tonix Pharmaceuticals Holding Corp.

Launch TNX-102 SL product for fibromyalgia

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
6 Feb 2025
Due
31 Dec 2025
Delivered
17 Nov 2025
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“Potential product launch in 2025”

What we found

Evidence strength A What the grades mean

FDA approved TNX-102 SL (TONMYA) on August 15, 2025, and Tonix commercially launched it in the U.S. on November 17, 2025, within the stated 2025 timeframe.

Checked 17 Sep 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Commercial launch
Indicative materiality
Medium rules
Action
Launch

How this entry was checked

  1. Commitment recordedRecorded from the company's filing.
  2. First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Tonix Pharmaceuticals Holding Corp.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2025-TNXP-000284 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.